Caring Ambassadors Program

Hepatitis C Newsletter

www.HepCChallenge.org

May 2011

 

Clinical Trials, Cohort Studies, Pilot Studies

 

Controlled release recombinant human interferon-α2b for treating patients with chronic hepatitis C genotype 1: a phase 2a clinical trial. Dzyublyk I, Yegorova T, Moroz L, et al. J Viral Hepat. 2011 Apr;18(4):271-9. doi: 10.1111/j.1365-2893.2010.01298.x.

http://www.ncbi.nlm.nih.gov/pubmed/20367790

 

Virological response is associated with decline in hemoglobin concentration during pegylated interferon and ribavirin therapy in hepatitis C virus genotype 1. Sievert W, Dore GJ, McCaughan GW, et al. Hepatology. 2011 Apr;53(4):1109-1117. doi: 10.1002/hep.24180.

http://www.ncbi.nlm.nih.gov/pubmed/21480317

 

Excess mortality in patients with advanced chronic hepatitis C treated with long-term peginterferon. Di Bisceglie AM, Stoddard AM, Dienstag JL, et al. Hepatology. 2011 Apr;53(4):1100-1108. doi: 10.1002/hep.24169.

http://www.ncbi.nlm.nih.gov/pubmed/21480316

 

Hepatitis C virus infection causes hypolipidemia regardless of hepatic damage or nutritional state: An epidemiological survey of a large Japanese cohort. Miyazaki T, Honda A, Ikegami T, et al. Hepatol Res. 2011 Apr 19. doi: 10.1111/j.1872-034X.2011.00803.x. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21501354

 

A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C (HEP-10-2210). Dienstag JL, Ghany MG, Morgan TR, et al. Hepatology. 2011 Apr 21. doi: 10.1002/hep.24370. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21520194

 

Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in Asian Patients. Sinn DH, Kim YJ, Lee ST, et al. J Gastroenterol Hepatol. 2011 Apr 18. doi: 10.1111/j.1440-1746.2011.06744.x. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21501223

 

Basic and Applied Science, Pre-Clinical Studies

 

A common polymorphism in the ABCB11 gene is associated with advanced fibrosis in hepatitis C but not in non-alcoholic fatty liver disease. Iwata R, Baur K, Stieger B, et al. Clin Sci (Lond). 2011 Apr;120(7):285-6.

http://www.ncbi.nlm.nih.gov/pubmed/20883210

Regulation of Infectious Genotype 1a Hepatitis C Virus Production by Domain III of NS5A. Kim S, Welsch C, Yi M, Lemon SM. J Virol. 2011 Apr 27. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21525356

 

Temporal Variations in the Hepatitis C Virus Intra-Host Population during Chronic Infection. Ramachandran S, Campo DS, Dimitrova ZE, Xia GL, Purdy MA, Khudyakov YE. J Virol. 2011 Apr 27. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21525348

 

Resistance mutations define specific antiviral effects for inhibitors of the hepatitis C virus (HCV) p7 ion channel. Foster TL, Verow M, Wozniak AL, et al. Hepatology. 2011 Apr 21. doi: 10.1002/hep.24371. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21520195

 

Novel Evolved Immunoglobulin (Ig)-Binding Molecules Enhance the Detection of IgM against Hepatitis C Virus. Cao J, Chen Q, Zhang H, et al. PLoS One. 2011 Apr 14;6(4):e18477.

http://www.ncbi.nlm.nih.gov/pubmed/21533225

 

Hepatitis C Virus Protects Human B Lymphocytes from Fas-Mediated Apoptosis via E2-CD81 Engagement. Chen Z, Zhu Y, Ren Y, et al. PLoS One. 2011 Apr 19;6(4):e18933.

http://www.ncbi.nlm.nih.gov/pubmed/21526201

 

Structural in silico analysis of cross-genotype-reactivity among naturally occurring HCV NS3-1073-variants in the context of HLA-A*02:01 allele. Antunes DA, Rigo MM, Silva JP, Cibulski SP, Sinigaglia M, Chies JA, Vieira GF. Mol Immunol. 2011 Apr 20. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21513985

 

The hepatitis C virus NS5A inhibitor (BMS-790052) alters the subcellular localization of the NS5A non-structural viral protein. Lee C, Ma H, Hang JQ, Leveque V, Sklan EH, Elazar

http://www.ncbi.nlm.nih.gov/pubmed/21513964

 

Serum chemokine levels are associated with the outcome of pegylated interferon and ribavirin therapy in patients with chronic hepatitis C. Yoneda S, Umemura T, Joshita S, et al. Hepatol Res. 2011 Apr 19. doi: 10.1111/j.1872-034X.2011.00802.x. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21504519

 

HIV/HCV Coinfection

 

The natural history of liver cirrhosis in HIV-hepatitis C virus-coinfected patients.

López-Diéguez M, Montes ML, Pascual-Pareja JF, et al.  AIDS. 2011 Apr 24;25(7):899-904.

http://www.ncbi.nlm.nih.gov/pubmed/21330908

 

Peginterferon alfa and ribavirin for chronic hepatitis C in patients eligible for shortened treatment, re-treatment or in HCV/HIV co-infection: a systematic review and economic evaluation. Hartwell D, Jones J, Baxter L, Shepherd J. Health Technol Assess. 2011 Apr;15(17):1-210.

http://www.ncbi.nlm.nih.gov/pubmed/21473834

 

Influence of antiretroviral therapy on liver disease. Kovari H, Weber R. Curr Opin HIV AIDS. 2011 Apr 20. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21508839

 

Treatment of acute hepatitis C infection in HIV-infected patients. Boesecke C, Rockstroh JK. Curr Opin HIV AIDS. 2011 Apr 23. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21519248

 

Very early prediction of response to HCV treatment with PEG-IFN-alfa-2a and ribavirin in HIV/HCV-coinfected patients. Araújo ES, Dahari H, Neumann AU, e al. J Viral Hepat. 2011 Apr;18(4):e52-60. doi: 10.1111/j.1365-2893.2010.01358.x.

http://www.ncbi.nlm.nih.gov/pubmed/20738775

 

Antiretroviral treatment interruption leads to progression of liver fibrosis in HIV-hepatitis C virus co-infection. Thorpe J, Saeed S, Moodie EE, Klein MB; for the Canadian Co-infection Cohort Study (CTN222). AIDS. 2011 Apr 24;25(7):967-975.

http://www.ncbi.nlm.nih.gov/pubmed/21330904

 

IL28B gene polymorphisms and viral kinetics in HIV/hepatitis C virus-coinfected patients treated with pegylated interferon and ribavirin. Rallón NI, Soriano V, Naggie S, et al. AIDS. 2011 Apr 18. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21505315

 

Felt and Enacted Stigma Among HIV/HCV-Coinfected Adults: The Impact of Stigma Layering. Lekas HM, Siegel K, Leider J. Qual Health Res. 2011 Apr 15. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21498828

 

Hepatitis B and C infection and liver disease trends among human immunodeficiency virus-infected individuals. Buskin SE, Barash EA, Scott JD, Aboulafia DM, Wood RW. World J Gastroenterol. 2011 Apr 14;17(14):1807-16.

http://www.ncbi.nlm.nih.gov/pubmed/21528052

 

Complementary and Alternative Medicine

 

A single arm phase II study of a Far-Eastern traditional herbal formulation (sho-sai-ko-to or xiao-chai-hu-tang) in chronic hepatitis C patients. Deng G, Kurtz RC, Vickers A, Lau N, Yeung KS, Shia J, Cassileth B. J Ethnopharmacol. 2011 Apr 17. [Epub ahead of print]

Source

http://www.ncbi.nlm.nih.gov/pubmed/21527335

 

 [Syndrome distribution among patients with chronic hepatitis C and interventions of integrated traditional Chinese and Western medicine: study protocol.] [Article in Chinese]

Nie HM, Gao YQ, Chen JJ. Zhong Xi Yi Jie He Xue Bao. 2011 Apr 15;9(4):365-373.

http://www.ncbi.nlm.nih.gov/pubmed/21486548

 

Epidemiology, Diagnostics, and Miscellaneous Works

 

Racial differences in hepatitis C treatment eligibility. Melia MT, Muir AJ, McCone J, et al. Hepatology. 2011 Apr 12. doi: 10.1002/hep.24358. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21488082

 

A New Combination of Blood Test and Fibroscan for Accurate Non-Invasive Diagnosis of Liver Fibrosis Stages in Chronic Hepatitis C. Boursier J, de Ledinghen V, Zarski JP, et al.

http://www.ncbi.nlm.nih.gov/pubmed/21468012

 

Quality of life in patients with various liver diseases: patients with HCV show greater mental impairment, while patients with PBC have greater physical impairment. Tillmann HL, Wiese M, Braun Y, et al. J Viral Hepat. 2011 Apr;18(4):252-61. doi: 10.1111/j.1365-2893.2010.01292.x.

http://www.ncbi.nlm.nih.gov/pubmed/20337922

 

Barriers to Providing Health Services for HIV/AIDS, Hepatitis C Virus Infection and Sexually Transmitted Infections in Substance Abuse Treatment Programs in the United States. Bini Deceased EJ, Kritz S, Brown LS Jr, Robinson J, Alderson D, Rotrosen J. J Addict Dis. 2011 Apr;30(2):98-109.

http://www.ncbi.nlm.nih.gov/pubmed/21491291

 

Risk factors associated with Hepatitis C among female substance users enrolled in community-based HIV prevention studies. Nurutdinova D, Abdallah AB, Bradford S, O'Leary CC, Cottler LB. BMC Res Notes. 2011 Apr 14;4(1):126. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21492467

 

A comparison of four fibrosis indexes in chronic HCV: Development of new fibrosis-cirrhosis index (FCI). Ahmad W, Ijaz B, Javed FT, et al. BMC Gastroenterol. 2011 Apr 21;11(1):44. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21507271

 

Potential role of safer injection facilities in reducing HIV and Hepatitis C infections and overdose mortality in the United States. Semaan S, Fleming P, Worrell C, Stolp H, Baack B, Miller M. Drug Alcohol Depend. 2011 Apr 22. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21515001

 

Abbott RealTime PCR assay is useful for evaluating virological response to antiviral treatment for chronic hepatitis C. Ikezaki H, Furusyo N, Ihara T, et al. J Infect Chemother. 2011 Apr 29. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21528383

 

Liver Cancer

 

A comparison of prognosis between patients with hepatitis B and C virus-related hepatocellular carcinoma undergoing resection surgery. Kao WY, Su CW, Chau GY, Lui WY, Wu CW, Wu JC. World J Surg. 2011 Apr;35(4):858-67.

http://www.ncbi.nlm.nih.gov/pubmed/21207029

 

Percutaneous Radiofrequency Ablation for Pulmonary Metastases from Hepatocellular Carcinoma: Results of a Multicenter Study in Japan. Hiraki T, Yamakado K, Ikeda O, et al. J Vasc Interv Radiol. 2011 Apr 29. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21531575

 

A comprehensive analysis of the dynamic biological networks in HCV induced hepatocarcinogenesis. He B, Zhang H, Shi T. PLoS One. 2011 Apr 19;6(4):e18516.

http://www.ncbi.nlm.nih.gov/pubmed/21526182

 

The toll-like receptor 2 (TLR2) -196 to -174 del/ins polymorphism affects viral loads and susceptibility to hepatocellular carcinoma in chronic hepatitis C. Nischalke HD, Coenen M, Berger C, et al. Int J Cancer. 2011 Apr 15. doi: 10.1002/ijc.26143. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21500195

 

Altered cytokine levels and increased CD4+CD57+ T cells in the peripheral blood of hepatitis C virus-related hepatocellular carcinoma patients. Shiraki T, Takayama E, Magari H, et al. Oncol Rep. 2011 Apr 12. doi: 10.3892/or.2011.1258. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21491089

 

Impact of radiation and hepatitis virus infection on risk of hepatocellular carcinoma.

Ohishi W, Fujiwara S, Cologne JB, et al. Hepatology. 2011 Apr;53(4):1237-45. doi: 10.1002/hep.24207.

http://www.ncbi.nlm.nih.gov/pubmed/21480328